WILMINGTON, N.C., (March 9, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has launched an innovative online portal linking clinical trial participants with biopharmaceutical companies, physicians and health care resources to enhance patient connectivity and improve retention in clinical trials.
PPD PatientView is a secure online technology empowering clinical trial participants to view, share and electronically archive medical information related to their illness, enabling them to play a more active role in managing their health and actively engaging them throughout the duration of a clinical trial.
“Regulatory agencies are requiring longer, more complex clinical studies, increasing the likelihood of patients leaving a clinical study before it’s completed,” said Mike Wilkinson, executive vice president and chief information officer for PPD. “The loss of patients during a trial can lead to increased costs and delay the trial’s completion. PPD PatientView empowers patients by enabling better communication with the study team, better connectivity with study activities and better access to information about their individual disease.”
PPD PatientView is customizable, allows patients online access to valuable health information and is a convenient way to stay in continual contact with the trial registry and monitoring program. The portal leverages Microsoft HealthVault, a personal health application platform that lets consumers gather, store and share health information online.
“PPD PatientView also provides patients access to the personal data they are contributing to the study on a per-visit basis,” said Dave Agrella, executive director for customer solutions for PPD. “We believe this kind of access increases their sense of involvement and engagement in contributing to the development of best-in-class medicines for their disease and ultimately improves the likelihood that they will remain in the trial until its completion.”
PPD PatientView is a part of PPD® Adaptive Solutions, the suite of customizable, flexible and integrated technology solutions that PPD deploys to meet each client’s needs in advancing their research initiatives. PPD and Microsoft have announced plans to jointly implement an innovative technology solution to improve efficiency in managing U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) programs. PPD also was recognized on the 2010 InformationWeek 500, a list of the nation’s most innovative users of business technology.
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the performance and value of PPD PatientView, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: rapid technological advances that make our products and services less competitive; the ability to attract and retain key personnel; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; risks associated with investments, such as impairments; success in sales growth; loss of large contracts; increased cancellation rates; risks associated with and dependence on collaborative relationships; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
Contacts
Media: Sue Ann Pentecost +919 456 5890 sueann.pentecost@ppdi.com
Analysts/Investors: Luke Heagle +910 558 7585 luke.heagle@ppdi.com
